Pharmacological studies in parkinsonian models, the dopamine/adenosine antagonism and the use of knock-out mice reinforced the view that targeting the A2AR in striatal neurons could be useful in the therapy of Parkinson’s disease [31,32,33,34,35,36]. This evidence concerns the gene ADORA2A and Parkinson disease.